Working… Menu
Trial record 35 of 36 for:    pharmacosmos

Iron Replacement in Oesophagogastric Neoplasia (IRON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01927328
Recruitment Status : Unknown
Verified October 2016 by Nottingham University Hospitals NHS Trust.
Recruitment status was:  Recruiting
First Posted : August 22, 2013
Last Update Posted : October 28, 2016
Pharmacosmos A/S
Information provided by (Responsible Party):
Nottingham University Hospitals NHS Trust

Brief Summary:

40 eligible patients with confirmed esophageal or gastric adenocarcinoma and anemia will be randomized to a control or intervention group for management of this anemia. The control group treatment will consist of standard treatments as governed by the clinical team (eg oral iron, blood transfusions) whilst the intervention group will be treated with intravenous iron III isomaltoside (Monofer ®).

It is hypothesized that intravenous iron supplementation is more efficacious than standard therapies.

Condition or disease Intervention/treatment Phase
Anemia Esophageal Cancer Gastric Cancer Drug: Iron isomaltoside 1000 Phase 4

Detailed Description:

Anemia is a common problem to affect patients diagnosed with esophageal or gastric cancer. This anemia is thought to be secondary to blood loss from the tumor, poor oral intake resulting from symptoms of the tumor, and impaired iron absorption secondary to neoplasia induced inflammatory processes.

Patients undergoing palliative chemotherapy for esophageal or gastric adenocarcinoma are thus prone to development or exacerbation of anemia during their chemotherapy, as this tumor is remains in situ.

Anemia results in symptoms such as shortness of breath, fatigue, lethargy and chest pain, which can all affect quality of life. Oral iron and blood transfusions are the current mainstay of treatment for the condition, yet both have their disadvantages. Oral iron is often poorly tolerated due to side effects including constipation, diarrhea, abdominal pain and nausea. Blood transfusions can also be administered but expose the patient to other risks including infection and transfusion associated reactions. In order to overcome these issues, intravenous iron preparations have been developed and have improved in safety.

This is a single-center, randomized, open label, clinical trial, which looks to investigate the efficacy of intravenous iron is in the treatment of anemia in patients with a diagnosis of esophageal or gastric adenocarcinoma.

Patients will be randomized to receive intravenous iron III isomaltoside (treatment group) or standard therapies decided by the clinical team (control). The outcomes reviewed will include the amount and frequency of blood transfusions received, changes in patient blood profiles and most importantly, patient quality of life scores. Patients will be followed from the start of their chemotherapy until the beginning of the third cycle.

The primary hypothesis to be tested is that intravenous iron will increase quality of life by reducing the symptoms of anemia. We also hypothesize that there will be a decrease in blood transfusion rate in this group and improved changes in hemoglobin and hematinics.

This is designed as a pilot study to determine the feasibility of a larger trial. Randomization will be performed using random allocation of opaque envelopes. All data will be confidentially recorded, as will drug reactions and side effects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma
Study Start Date : August 2013
Estimated Primary Completion Date : August 2017
Estimated Study Completion Date : August 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia Iron

Arm Intervention/treatment
No Intervention: Control
Standard Care as determined by the clinical team
Active Comparator: Iron isomaltoside 1000
Intravenous Iron Isomaltoside 1000 (Monofer®)will be administered in line with the summary of product characteristics.
Drug: Iron isomaltoside 1000
Other Name: Monofer®

Primary Outcome Measures :
  1. Hemoglobin differences between groups [ Time Frame: 8 months ]
    This will govern the magnitude of treatment effect, and hence aid design of a larger study.

Secondary Outcome Measures :
  1. Differences in quality of life [ Time Frame: 0-14 weeks ]
    To compare quality of life scores as determined by the EQ-5D and FACT-An questionnaires between treatment groups

  2. Number of allogenic red blood cell transfusions administered [ Time Frame: 0-14 weeks ]
    To investigate if the number of units transfused per participant, the number of participants whom received a blood transfusion and the total number of units of blood transfused differs between the two study arms. This period monitored will begin at enrolment into the study, and cease at the start of the third cycle of chemotherapy

  3. Differences in hematinic markers. [ Time Frame: 0 - 14 weeks ]
    To evaluate if hematinic markers (ferritin, iron, transferrin, transferrin) differ between treatment arms.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant is willing/able to give informed consent for study participation.
  • Male or Female, aged 18+
  • Anemic with hemoglobin values <13 g d/L for males & < 11.5 g/dL for females.
  • Diagnosed with histologically proven esophageal,gastric or Gastro-esophageal Junctional adenocarcinoma.
  • Treatment selected is palliative chemotherapy.
  • Medically fit for initiation of palliative chemotherapy.
  • Able (in the Investigators opinion) & willing to comply with all study aspects.
  • Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.

Exclusion Criteria:

  • Patients who following investigation do not have a histological diagnosis of upper GI adenocarcinoma
  • Female participants who are pregnant, lactating or planning a pregnancy during the course of the study.
  • Patients with evidence of iron overload or disturbances in utilization of iron as stated in the product Summary of Product Characteristics.
  • Known hematological disease that, in the investigators opinion would confound any changes in blood results.
  • Features necessitating urgent surgery.
  • Previous allergy to intravenous iron or related iron products.
  • Patients who are unable to consent.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  • Donation of blood during the study.
  • Prisoners and minors (<18 years).
  • Non-iron deficiency anaemia (e.g. haemolytic anaemia).
  • Hypersensitivity to the active substance or to any of the excipients.
  • Patients with a history of asthma, allergic eczema or other atopic allergy.
  • Decompensated liver cirrhosis and hepatitis.
  • Rheumatoid arthritis with symptoms or signs of active inflammation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01927328

Layout table for location contacts
Contact: Barrie D Keeler, FRCS 0115 82 31145
Contact: Austin G Acheson, MD FRCS 0115 82 31147

Layout table for location information
United Kingdom
Nottingham Univeristy Hospitals NHS Trust Recruiting
Nottingham, Nottinghamshire, United Kingdom, NG7 2UH
Contact: Barrie D Keeler, FRCS    0115 82 31145   
Principal Investigator: Austin G Acheson, MD FRCS         
Principal Investigator: Barrie D Keeler, FRCS         
Sponsors and Collaborators
Nottingham University Hospitals NHS Trust
Pharmacosmos A/S
Layout table for investigator information
Principal Investigator: Barrie D Keeler, FRCS University of Nottingham
Study Chair: Austin G Acheson, MD FRCS University of Nottingham

Layout table for additonal information
Responsible Party: Nottingham University Hospitals NHS Trust Identifier: NCT01927328     History of Changes
Other Study ID Numbers: 12GA029
2013-000209-22 ( EudraCT Number )
First Posted: August 22, 2013    Key Record Dates
Last Update Posted: October 28, 2016
Last Verified: October 2016
Keywords provided by Nottingham University Hospitals NHS Trust:
Palliative therapy
Palliative care
Palliative treatments
Esophageal Cancer
Gastric Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Esophageal Neoplasms
Hematologic Diseases
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Head and Neck Neoplasms
Esophageal Diseases
Iron isomaltoside 1000
Ferric Compounds
Trace Elements
Growth Substances
Physiological Effects of Drugs